Tirzepatide, sold in the UK as Mounjaro, is a once-weekly injection made by Eli Lilly that acts on two gut hormone receptors, GIP and GLP-1. It is licensed for weight management alongside a reduced-calorie diet and increased physical activity, and it is a prescription-only medicine: no one in the UK can obtain it lawfully without a consultation with a qualified prescriber.
What confuses people is not what it does, but how to get near it. Someone may read that NICE has recommended tirzepatide for the NHS, ask their GP, and be told they do not qualify. Another may find a clinic offering an online assessment and wonder whether it is legitimate.
This article sets out how access works at the time of writing: what the NICE recommendation covers, why NHS availability is being phased in, who currently meets the primary-care criteria, and how the regulated private route works.
The NHS route: what NICE TA1026 actually did
NICE technology appraisal TA1026 recommends tirzepatide as an option for managing overweight and obesity in adults, alongside diet and physical activity. That matters: it means the medicine has been assessed as clinically effective and a reasonable use of NHS money for a defined group. Where it is misread is in what a recommendation obliges the NHS to do, and how quickly.
Why a recommendation did not mean immediate availability
NICE assesses whether a treatment should be available. It does not create the clinics, staff and follow-up systems needed to prescribe and monitor it at scale. Obesity is very common in the UK, so a broad eligibility bar would cover an enormous number of adults, and a medicine requiring dose titration and regular review is not a single prescription and done.
NHS England is therefore implementing tirzepatide through a phased rollout rather than switching it on everywhere at once. The effect is that meeting NICE’s overall criteria and being eligible for an NHS prescription today are not the same thing.
The current primary-care criteria
In the initial phase in primary care, access is limited to a much narrower group than the full NICE population. Broadly, that means adults with:
- a body mass index of 35 or above, adjusted using lower thresholds for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds; and
- four weight-related conditions, drawn from dyslipidaemia, hypertension, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes.
The requirement for four conditions surprises most people. It is a deliberate prioritisation choice, targeting the earliest supply at those carrying the greatest weight-related health burden. Someone with a BMI of 36 and two conditions is not being told the medicine would not help them, only that they are not in the first phase.
Where specialist weight management services fit
Primary care is not the only NHS door. Specialist weight management services, sometimes called tier 3 or tier 4, are multidisciplinary teams typically including dietitians, psychologists, specialist nurses and consultants. They may work to different criteria from general practice during the rollout, and can consider medication as one part of a broader programme. Access is usually by referral and waiting times vary, so for many people the realistic NHS conversation starts with a GP appointment about a referral rather than a prescription.
Why criteria differ locally, and how to check
Integrated care boards commission services in their area and decide how national guidance is implemented locally. The pace of the rollout, which services prescribe, and the referral routes into them can differ between one ICB and its neighbour.
The only reliable way to find out where you stand is to check locally: ask your GP practice directly, or look at your ICB’s published position on weight management services, often available on its website. General articles, including this one, cannot tell you what your area is currently doing.
The three-year review
The phased approach is not meant to be permanent. NICE has indicated it will review the guidance after three years, and the rollout phases are expected to widen as capacity develops. Someone who does not qualify now may qualify later, which is worth knowing before making a long-term decision on today’s thresholds.
The regulated private route
The other lawful route is a private prescription through a registered pharmacy or clinic. This is a regulated pathway, not a workaround. It changes who pays and how quickly an assessment happens; it does not change the fact that the medicine is prescription-only, nor the clinical judgement applied before supply.
How an online consultation works
A regulated online pharmacy will ask you to complete a structured clinical questionnaire first, covering height and weight, medical history, current medicines, allergies, previous weight management attempts, and anything that would make treatment unsuitable. Many services also ask for identification or a photograph to verify weight-related information.
A prescriber then reviews the submission and may approve, decline, or ask follow-up questions before deciding. Only after a prescription is issued can the pharmacy dispense. If you are researching how to buy mounjaro online in the UK, that consultation step is what distinguishes a lawful service from an unlawful one, and it should never be optional.
What a prescriber checks
A prescriber is making a clinical decision, not processing an order. In practice they consider:
- whether your BMI and any weight-related conditions meet the service’s stated eligibility;
- contraindications, including pregnancy or breastfeeding, and a personal or family history of medullary thyroid carcinoma or MEN2;
- conditions requiring caution, such as a history of pancreatitis, severe gastrointestinal disease or diabetic retinopathy;
- interactions with existing medicines, including the higher risk of low blood sugar alongside insulin or a sulfonylurea;
- whether lifestyle measures have been tried, since the medicine is licensed for use alongside diet and activity rather than instead of them.
UK-registered pharmacies publish their regulatory details so you can verify them independently. A service such as curedpharmacy.com, for example, lists its GPhC registration and superintendent pharmacist and requires a clinical assessment reviewed by a prescriber before any supply. Checking those details on the GPhC register at pharmacyregulation.org.uk takes a couple of minutes and is worth doing every time.
Why prescribers decline
Regulated services do refuse requests, and a service that never refuses anyone would be the one to worry about. Common reasons include a BMI below the threshold, a contraindication disclosed in the questionnaire, an incomplete or inconsistent history, pregnancy or planning a pregnancy, being under 18, or answers suggesting an eating disorder. A prescriber may also decline a dose increase if side effects are not settling.
A refusal is not a queue to be joined elsewhere. If a regulated prescriber has said no, seeking out a seller who says yes without asking questions removes the only safeguard in the process.
What ongoing review looks like
Treatment is not a single transaction. The standard approach is 2.5 mg weekly for four weeks as a starting dose rather than a treatment dose, then increases of 2.5 mg no sooner than every four weeks, up to a maximum of 15 mg weekly, guided by response and tolerance. Prescribers often hold at a lower dose if it is working and well tolerated.
Repeat supplies should therefore involve a check on weight change, side effects and whether continuing is appropriate. There is also specific MHRA advice for people using oral contraceptives: use an additional barrier method, or switch to a non-oral method, for four weeks after starting tirzepatide and for four weeks after each dose increase, because delayed gastric emptying can reduce absorption.
What it costs at the time of writing
Private treatment is paid month by month and the price rises with the dose. At the time of writing, one UK pharmacy’s listed prices for four-week packs of the Mounjaro KwikPen are £145 for 2.5 mg, £179 for 5 mg, £220 for 7.5 mg, £245 for 10 mg, £270 for 12.5 mg and £287 for 15 mg. Prices vary between providers and change, so treat any figure as a snapshot, and consider affordability over months rather than weeks.
NHS route and regulated private route compared
FeatureNHS routeRegulated private routeEligibilityPhased. In primary care initially BMI 35+ (adjusted for ethnicity) plus four weight-related conditions; specialist services may apply different criteriaSet by the service within the licence, commonly 18+ with BMI 30+, or BMI 27+ with at least one weight-related condition, where lifestyle change alone has not been enoughCost to the patientNHS prescription charge, or free if exemptFull cost, paid per four-week pack, rising with doseWaitingDepends on local commissioning and referral waits for specialist services; may not be available in your area yetAssessment usually reviewed within days, though supply still depends on the prescriber’s decisionMonitoring and supportUsually part of a wider service, often with dietetic and behavioural inputPrescriber review at repeat supply; depth of wraparound support varies by providerPrescription requiredYesYes, without exception
Neither column is the better one in the abstract. The NHS route places treatment inside a broader service at no direct cost, and for those who meet the current criteria it is generally the sensible first conversation. The private route removes the wait for people who meet a service’s own eligibility but not the NHS phase criteria, at a recurring cost they carry themselves.
Side effects and who it is not suitable for
Whichever route someone takes, the medicine and its risks are the same. The most common side effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, reduced appetite and abdominal discomfort. These are usually worst in the first few weeks and after each dose increase, which is part of the reason for slow titration.
Less common effects include injection-site reactions, fatigue, dizziness and hair thinning. Serious but uncommon problems include pancreatitis, gallbladder problems, and dehydration or kidney injury from persistent vomiting. Tirzepatide is not suitable during pregnancy or breastfeeding, or for people with a personal or family history of medullary thyroid carcinoma or MEN2.
Pens are stored in a fridge at 2–8°C, with a limited period permitted out of the fridge at up to 30°C. Follow the patient information leaflet supplied with the medicine and your pharmacist’s advice, and speak to a GP, pharmacist or prescriber about anything that concerns you.
Avoiding the unregulated market
The MHRA has repeatedly warned about counterfeit weight-loss pens sold through social media and unregistered websites. Products from those sources may contain the wrong drug, the wrong dose, or nothing active at all, and there is no prescriber, no traceable supply chain and no recourse.
Three checks cover most of the risk: confirm the pharmacy and its superintendent pharmacist on the GPhC register, look for the registered premises number and distance-selling logo, and confirm a real consultation is required before supply. A seller offering the medicine with no questions asked is not offering a shortcut.
Questions people commonly ask
Can I ask my GP to prescribe Mounjaro privately?
GPs work within NHS commissioning arrangements and local formularies, so a GP generally cannot issue an NHS prescription outside the agreed criteria. Some may discuss a private prescription, but this varies by practice. It is still worth raising with your GP, who can advise on referral options.
Does paying privately mean I skip the clinical assessment?
No. Mounjaro is a prescription-only medicine in the UK regardless of who pays. A regulated private service must still carry out an assessment reviewed by a prescriber, and can decline. Paying changes the funding route, not the legal or clinical requirements.
If I start privately, can I move to the NHS later?
Possibly, if you come to meet the criteria in force in your area as the rollout widens, but there is no guarantee and no automatic transfer. If you are taking the medicine privately, tell your GP so it is recorded in your notes and considered alongside your other care.
How much weight will I lose?
No one can tell you that. In the SURMOUNT-1 trial, which ran 72 weeks in adults with obesity or overweight with a weight-related condition and without type 2 diabetes, mean weight reduction alongside diet and exercise was roughly 15% at 5 mg, about 19.5% at 10 mg and about 21% at 15 mg. Those are trial averages, not a forecast for any individual.
Where that leaves you
Access to tirzepatide in the UK runs along two lawful tracks. The NHS track is real but phased, tightly targeted in primary care for now and shaped by what your local ICB has commissioned, with a NICE review due after three years. The regulated private track is open to a wider group but carries an ongoing cost and the same clinical gatekeeping.
The useful first step is the least dramatic one: find out what your area is offering and have the conversation with your GP. Whatever you decide, the medicine works as part of a package that includes diet, activity and ongoing support, not as a replacement for them.
This article is general information about how access to a licensed medicine works in the UK. It is not medical advice and it is not a recommendation for your circumstances. Speak to your GP, pharmacist or another qualified healthcare professional before starting, changing or stopping any treatment, and read the patient information leaflet supplied with the medicine.
